Quoin Pharmaceuticals, Ltd. — Director's Dealing 2023

Oct 30, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2023-10-26

Reporting Person: Carter Denise P. (Director, Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-10-26	Share Option (Right to Buy)	$5.75	A	80966	Acquired	2033-10-26	American Depositary Share (80966)	Direct

Footnotes

F1: The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"), with sixty thousand (60,000) ordinary shares of the Issuer represented by one (1) ADS.

F2: The option vests in four annual installments with 20% vesting on each of October 26, 2024, 2025 and 2026 and 40% vesting on October 26, 2027.